Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Medicines Co. to Buy ProFibrix, Depending on Study

By Pharmaceutical Processing | June 4, 2013

 

PARSIPPANY, N.J. (AP) — Drug developer The Medicines Co. plans to buy ProFibrix BV in a deal that will hinge on late-stage study results for a topical powder that the company is developing to stop bleeding during or after surgery.

Medicines Co. said Tuesday it will make a $10 million option payment upfront and then will review late-stage results from a study of 719 surgical patients with mild to moderate surgical bleeding. Those results are expected in the third quarter. If Medicines Co. is satisfied with them, it will purchase all outstanding shares of ProFibrix, which is based in the Netherlands.

Medicines Co. did not say how much it would pay for each share. The U.S. drug developer did say ProFibrix shareholders might also receive additional payments tied to U.S. and European regulatory approvals and sales milestones.

ProFibrix, which was formed in 2004, is developing Fibrocaps, which mixes the blood clotting proteins fibrinogen and thrombin to form the dry topical powder.

Medicines Co. makes the anti-clotting drug Angiomax, among other products. Last fall, it said it was ending development of a drug labeled as MDCO-2010 designed to reduce bleeding during surgery because of safety concerns.

Shares of Medicines Co. finished at $33.49 on Monday and have climbed nearly 40 percent so far this year.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE